These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 25258343

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R, de Thé H.
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Function of PML-RARA in Acute Promyelocytic Leukemia.
    Testa U, Pelosi E.
    Adv Exp Med Biol; 2024 Jun; 1459():321-339. PubMed ID: 39017850
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
    Isakson P, Bjørås M, Bøe SO, Simonsen A.
    Blood; 2010 Sep 30; 116(13):2324-31. PubMed ID: 20574048
    [Abstract] [Full Text] [Related]

  • 15. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
    Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, de Thé H.
    Cancer Cell; 2010 Jul 13; 18(1):88-98. PubMed ID: 20609355
    [Abstract] [Full Text] [Related]

  • 16. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Xu L, Zeng Z, Zhang W, Ren G, Ling X, Huang F, Xie P, Su Y, Zhang XK, Zhou H.
    Oncotarget; 2017 Feb 14; 8(7):12311-12322. PubMed ID: 28129653
    [Abstract] [Full Text] [Related]

  • 17. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, Yu JJ, Zhang XW, Shang S, Liu SS, Yu JM, Han MZ, Huang B, Zhang TT, Li X, Jiang JD, Hu ZW.
    Cancer Cell; 2017 May 08; 31(5):697-710.e7. PubMed ID: 28486108
    [Abstract] [Full Text] [Related]

  • 18. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
    Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de Thé H.
    Clin Cancer Res; 2009 Oct 15; 15(20):6321-6. PubMed ID: 19808868
    [Abstract] [Full Text] [Related]

  • 19. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H.
    Trends Mol Med; 2012 Jan 15; 18(1):36-42. PubMed ID: 22056243
    [Abstract] [Full Text] [Related]

  • 20. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
    Yang WC, Shih HM.
    Oncogene; 2013 Oct 24; 32(43):5167-75. PubMed ID: 23208507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.